腎細胞癌におけるcDNA microarrayにより得られた予後予測遺伝子群の検定

肾细胞癌cDNA微阵列检测预后预测基因

• 批准号: 15790853
• 负责人: 高橋 正幸
• 金额: $ 1.47万
• 依托单位: The University of Tokushima
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15790853/
• 关键词: 腎細胞癌; cDNA microarray; gene expression profiling; prognosis; マイクロアレイ; 予後

われわれは、約20,000のcDNAをspotしたmicroarrayを用いて、様々な病期、細胞分化度、予後の異なる淡明型腎細胞癌組織のgene expression profilingを行い、gene expression profilingは、淡明型腎細胞癌の予後と強く相関することを同定した。これを基に、統計学的解析を行い、淡明型腎細胞癌の予後予測可能な51の遺伝子からなる遺伝子群を同定した。これらは、いわゆるtraining setから導き出された遺伝子群であるため、われわれは、解析をしていない淡明型腎細胞癌、いわゆるtest setにおいても、これらの予後予測遺伝子群が、予後を予測可能かどうか検討した。各サンプルから得られたデータから、それぞれわれわれが同定した予後予測可能な遺伝子群の発現データを抽出した。それぞれの遺伝子の発現が、2群の鑑別にどれくらい関連があるか、また2群の中央値からどれだけ発現値が離れているかを計算し、これらを各群にvoteする"weighted votes"を行った。これらの総計としてprediction strengthを計算し,新しく解析した淡明型腎細胞癌が予後の良い群と不良群のどちらの遺伝子発現を持っているか統計学的に判定した。(Golub et al. Science Vol.286 531-537,1999)。新しく解析した淡明型腎細胞癌10例のうち経過観察期間が十分でない患者が含まれていたため、正確に予見された患者の割合は求めることができなかったが、2例は正確に予見され,一般に予後の悪いgrade 3の2例はpoor outcome groupに,一般に予後の良いgrade 1の2例はgood outcome groupと診断された。この予後予測可能な遺伝子群は、最初に検討したtraining setに比べて、精度はやや低下したが、淡明型腎細胞癌症例の予後予測がある程度可能ではないかと考えられた。現在、さらに症例数を増加し、予後予測遺伝子群そのものの再検討を施行中である。

The histology of cDNA, spot, microarray, disease stage, degree of differentiation, histology of gene expression profiling, gene expression profiling, and light-light type of cancer were detected by RT-PCR, RT-PCR, RT-PCR and RT-PCR. The basis of statistics, the analysis of statistics, and the light type of "cell cancer" predicted that it was possible that the subgroup was the same in the future. This is the first time that the subgroup of the cancer has been detected. The subgroup of the cell cancer has been detected. The test set has been detected and the subgroup has been tested later. In each case, it is necessary to determine the possibility that the sub-group may show that there is a problem in the future. In each of the two groups, there is a significant difference between the two groups, the second group, the second group, the second group In this paper, we calculated the prediction strength calculation, and the new analysis showed that the good group, the bad group, the poor group, the healthy group, the poor group, the healthy group, the poor group, (Golub et al. Science Vol.286 531-537 1999). According to the new analysis, there were 10 cases of light-clear malignant cell carcinoma and 10 cases of normal cell carcinoma. during the observation period, there were 10 cases of mild cancer and 10 cases of normal cytoma. in the new analysis, there were 10 cases of light-clear malignant cell carcinoma and 10 cases of normal cell carcinoma. in the new analysis, 10 cases of light-clear malignant cell carcinoma were diagnosed by the new method, and 10 cases were diagnosed by clinical observation. The patients were diagnosed correctly, 2 cases were correctly diagnosed, 2 cases were diagnosed as grade 3, 2 cases were diagnosed as poor outcome group, and 2 cases were diagnosed as good outcome group. In the future, it is possible that the subgroup, the training set, the accuracy, the degree of cancer, the degree of cancer. At present, there is a rapid increase in the number of cases, and the number of cases in the subgroup will be tested later.

项目成果

Molecular subclassification of kidney tumors and the discovery of new diagnostic markers

• DOI: 10.1038/sj.onc.1206869
• 发表时间: 2003-10-02
• 期刊: ONCOGENE
• 影响因子: 8
• 作者: Takahashi, M;Yang, XMJ;Teh, BT
• 通讯作者: Teh, BT

Chen J: "The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas"Cancer Cell. 4. 405-413 (2003)

Chen J：“t(1;3) 断点跨越基因 LSAMP 和 NORE1 参与透明细胞肾细胞癌”Cancer Cell。

Takahashi M: "Molecular subclassification of kidney tumors and the discovery of new diagnostic markers."Oncogene. 22. 6810-6818 (2003)

Takahashi M：“肾肿瘤的分子亚分类和新诊断标记物的发现。”癌基因。

Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics

肾细胞癌的基因表达谱及其在诊断、预后和治疗中的意义

• 发表时间: 2003
• 期刊: Advanced in Cancer Research 89
• 作者: Takahashi M;Takahashi M
• 通讯作者: Takahashi M